We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

529 hedge funds and large institutions have $17.9B invested in Abiomed Inc in 2018 Q3 according to their latest regulatory filings, with 71 funds opening new positions, 202 increasing their positions, 184 reducing their positions, and 63 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more first-time investments, than exits

New positions opened: 71 | Existing positions closed: 63

12% more capital invested

Capital invested by funds: $16B → $17.9B (+$1.93B)

10% more repeat investments, than reductions

Existing positions increased: 202 | Existing positions reduced: 184

0% more funds holding

Funds holding: 527529 (+2)

5% less funds holding in top 10

Funds holding in top 10: 2120 (-1)

41% less call options, than puts

Call options by funds: $251M | Put options by funds: $424M

Holders
529
Holders Change
+2
Holders Change %
+0.38%
% of All Funds
12.09%
Holding in Top 10
20
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-4.76%
% of All Funds
0.46%
New
71
Increased
202
Reduced
184
Closed
63
Calls
$251M
Puts
$424M
Net Calls
-$173M
Net Calls Change
-$128M
Name Holding Trade Value Shares
Change
Change in
Stake
NA
151
Navellier & Associates
Nevada
$10.1M +$217K +551 +3%
Arrowstreet Capital
152
Arrowstreet Capital
Massachusetts
$9.86M +$8.64M +21,918 New
AIM
153
Allen Investment Management
New York
$9.85M
Simplex Trading
154
Simplex Trading
Illinois
$9.57M +$1.9M +4,815 +29%
SI
155
Stephens Inc
Arkansas
$9.42M +$8.26M +20,949 New
PAMU
156
Pictet Asset Management (UK)
United Kingdom
$9.42M -$378K -960 -4%
AAM
157
Advisors Asset Management
Colorado
$9.35M +$4.73K +12 +0.1%
Aviva
158
Aviva
United Kingdom
$9.23M +$8.09M +20,527 New
WMSA
159
Weiss Multi-Strategy Advisers
New York
$8.54M -$197K -500 -3%
HSBC Holdings
160
HSBC Holdings
United Kingdom
$8.52M -$3.82M -9,703 -34%
AC
161
Ascend Capital
California
$8.19M +$7.18M +18,215 New
APG Asset Management
162
APG Asset Management
Netherlands
$8.09M +$3.43M +8,700 +71%
KC
163
Kepos Capital
New York
$7.89M +$6.91M +17,540 New
SI
164
Shaker Investments
Ohio
$7.86M -$3.94K -10 -0.1%
BNP Paribas Financial Markets
165
BNP Paribas Financial Markets
France
$7.79M +$451K +1,144 +7%
Squarepoint
166
Squarepoint
New York
$7.66M -$3.11M -7,884 -32%
Treasurer of the State of North Carolina
167
Treasurer of the State of North Carolina
North Carolina
$7.51M +$2.83M +7,167 +75%
Handelsbanken Fonder
168
Handelsbanken Fonder
Sweden
$7.42M +$2.76M +7,000 +74%
Wellington Management Group
169
Wellington Management Group
Massachusetts
$7.29M +$4.48M +11,358 +234%
Royal London Asset Management
170
Royal London Asset Management
United Kingdom
$7.25M +$6.36M +16,122 New
WBC
171
Westpac Banking Corp
Australia
$7.25M +$700K +1,775 +12%
Thrivent Financial for Lutherans
172
Thrivent Financial for Lutherans
Minnesota
$7.19M +$315K +799 +5%
AIG
173
American International Group
New York
$7.11M +$681K +1,727 +12%
ZIG
174
Zurich Insurance Group
Switzerland
$7.1M +$6.22M +15,791 New
BNP Paribas Asset Management
175
BNP Paribas Asset Management
France
$7.03M +$2.29M +5,799 +59%

ABMD Hedge Fund Activity: Q3 2018 in Review

529 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q3 2018, worth a combined $17.9B — up 12% from $16B a quarter earlier.

Buyers outnumbered sellers: 71 funds opened new ABMD positions and 63 closed out — a net gain of 8 holders — while 202 added to existing stakes and 184 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $314M. The largest seller was Baillie Gifford & Co, cutting an estimated $513M.

  • 529 institutional investors held Abiomed Inc (ABMD) as of Q3 2018, up from 527 in Q2 2018.
  • Funds reported $17.9B of Abiomed Inc stock for Q3 2018, up 12% quarter-over-quarter.
  • 71 funds opened new Abiomed Inc positions in Q3 2018 and 63 closed out, a net change of +8 holders.
  • The largest Abiomed Inc buyer in Q3 2018 was AQR Capital Management, an estimated $314M added.
  • The largest Abiomed Inc seller in Q3 2018 was Baillie Gifford & Co, an estimated $513M sold.

Based on aggregated 13F filings for Q3 2018.